Practical information for your patients

ELIQUIS® (apixaban) Patient information booklets

These booklets may be read in its electronic form (PDF) or may be printed.

Please note: Switching from warfarin to ELIQUIS should only be done under close clinical supervision. Any prescribing decision should only be made by the prescribing healthcare professional based on sound clinical reasons and after appropriate assessment with patient involvement in the decision-making.

If a Patient Information Booklet is printed, please ensure that:

  • It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in entirety
  • Its content is not edited or altered in any way
  • It is printed in colour
  • It is printed on A4 size paper
  • The pages are placed in the correct order as per the page numbering
  • ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery1


  • NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association   TIA = Transient Ischaemic Attack   DVT = Deep Vein Thrombosis   PE = Pulmonary Embolism


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or